Eli Lilly and Company (LLY)
Sagimet Biosciences' Denifanstat Remains A Strong Buy Despite Eli Lilly's Tirzepatide
Sagimet Biosciences is progressing with Denifanstat research targeting MASH, acne, and cancer with promising Phase 2b trial results. Denifanstat is progressing toward Phase 3 trials, with positive results reinforcing its potential, especially for hepatic-impaired patients. Eli Lilly's Tirzepatide presents strong competition for Denifanstat in MASH treatment, showing higher efficacy in recent trials.
Here is What to Know Beyond Why Eli Lilly and Company (LLY) is a Trending Stock
Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
1 Weight Loss Pharma Stock to Buy, and 1 to Consider
Big pharmas and biotechs alike are rushing to develop weight loss therapies. Eli Lilly's blockbuster products are likely to remain profitable and relevant.
Eli Lilly (LLY) Beats Stock Market Upswing: What Investors Need to Know
In the most recent trading session, Eli Lilly (LLY) closed at $807.79, indicating a +0.39% shift from the previous trading day.
Eli Lilly's $123 billion market value drop: A strategic buying opportunity?
Eli Lilly & Co (NYSE: LLY) has recently experienced a dramatic $123 billion decline in market value. This significant drop follows positive developments from competitors, notably Viking Therapeutics Inc and Roche Holding AG, who made announcements regarding their weight loss drugs.
What Will Be the Best Weight Loss Drug Stock of 2030: Eli Lilly, or Novo Nordisk?
The market for weight loss therapies is going to get larger and larger. Novo Nordisk and Eli Lilly both have powerful new candidates in the pipeline.
Bull Market Buys: 2 Growth Stocks to Own for the Long Run
Eli Lilly and Regeneron are among the world's leading drugmakers. Both stocks have performed exceptionally well in recent years.
Pharmaceutical stocks to watch for end of 2024
Pharma stocks can be strong investments regardless of economic conditions, as this stability arises because the demand for medications and healthcare services remains steady, even when prices rise.
Watch These Eli Lilly Stock Price Levels as Weight-Loss Drug Competition Rises
Eli Lilly (LLY) shares dropped more than 4% on Thursday, continuing a hasty retreat from their record high earlier this month, as investors assessed the possible impact of a promising new weight-loss injection developed by Viking Therapeutics (VKTX) on the drugmaker's own weigh anti-obesity drug, Mounjaro. Last week, Eli Lilly shares tumbled after Swiss pharmaceutical firm Roche Holding AG said its new non-injectable weight-loss drug has shown encouraging early stage data.
Is Eli Lilly Stock Headed Toward $1300 Levels?
Eli Lilly stock (NYSE: LLY) has seen its stock rise by around 50% this year, outperforming the broader indices, with the S&P 500 up over 15%. The stock now trades at 63x projected 2024 earnings of $13.75 per share.
Why Weight Loss Drug Developer Stocks Tumbled on Thursday
A clinical-stage biotech is coming for their lunch. It aims to advance its own weight-loss drug to a phase 3 clinical study in the very near future.
3 Companies Gearing Up for a Stock Split
Sometimes, the success of a company can take the stock so high that it pushes investors away. It is due to this reason that the management announces a stock split.
